Tumours showed robust downregulation of SWI/SNF targets and AR, ERG, MYC and Ki67 after five days of AU-15330 treatment, both when administered alone or with enzalutamide (Fig. 4c, Extended Data Fig. 10c–e). Here, SMARCA1 is linked to neoplasm.